If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Parenteral Nutrition." In 2019 the UK experienced a severe shortage of TPN bags due to safety restrictions at the sole manufacturing site, operated by Calea. The National Health Service described the situation as an emergency.
In 2019, the Economist Intelligence Unit's biannual Worldwide Cost of Living survey ranked Moscow 102nd among the 133 most expensive cities. ECA International's Cost of Living 2019 Survey ranked Moscow 120th among 482 locations globally.
Rubidium and caesium were the first elements to be discovered using the spectroscope, invented in 1859 by Robert Bunsen and Gustav Kirchhoff. The next year, they discovered caesium in the mineral water from Bad Dürkheim, Germany. Their discovery of rubidium came the following year in Heidelberg, Germany, finding it in the mineral lepidolite. The names of rubidium and caesium come from the most prominent lines in their emission spectra: a bright red line for rubidium (from the Latin word rubidus, meaning dark red or bright red), and a sky-blue line for caesium (derived from the Latin word caesius, meaning sky-blue). Around 1865 John Newlands produced a series of papers where he listed the elements in order of increasing atomic weight and similar physical and chemical properties that recurred at intervals of eight; he likened such periodicity to the octaves of music, where notes an octave apart have similar musical functions. His version put all the alkali metals then known (lithium to caesium), as well as copper, silver, and thallium (which show the +1 oxidation state characteristic of the alkali metals), together into a group. His table placed hydrogen with the halogens.
Absinthe makes you crazy and criminal, provokes epilepsy and tuberculosis, and has killed thousands of French people. It makes a ferocious beast of the man, a martyr of the woman, and a degenerate of the infant, it disorganizes and ruins the family and menaces the future of the country.
Progestogens, including both progesterone and progestins, are used medically in hormonal birth control, hormone therapy, to treat gynecological disorders, to suppress sex hormone levels for various purposes, and for other indications.
Sources: en.wikipedia.org
=== Phase 2 === Acetylcysteine lysinate (L-lysine-N-acetyl-L-cysteinate; N-acetylcysteine lysinate; Nacystelyn) – antioxidant Aminolevulinic acid (ALA; BF-200 ALA) – photosensitizer Cannabidiol topical (CBD; BTX-1204; BTX-1308; BTX-1503; BTX-1702; BTX-1801; PBX-1308) – cannabinoid Dimethylcurcumin (ASCJ-9; AJ-101; ASC-J9) – androgen receptor degradation enhancer Imsidolimab (ANB-019) – monoclonal antibody against the interleukin-36 receptor Ivermectin topical (CD-5024; Soolantra) – non-mammalian chloride channel opener LYS-006 – leukotriene A4 hydrolase (LTA4H) inhibitor Methyl aminolevulinate (MAL; CD06809-41; Luxerm; MAL-PDT; Metvix; Metvixia; P-1202; Visonac) – photosensitizer NAI Acne (BI-Acne; BI-K-0376; CB-06-01; CB-06-04; NAI-003; NAI-Acne; VIC-acne) – peptide elongation factor Tu inhibitor Omiganan (CLS-001; CPI-226; MBI-226; MBI-594AN; MX-226; MX-594AN; Omigard) – antiseptic/antibacterial Pyrilutamide (EX-A5504; HY-145451; KX–826) – antiandrogen (androgen receptor antagonist) Tretinoin topical – retinoid (retinoic acid receptor agonist) VB-1953 – antibiotic and toll-like receptor antagonist
=== Hart House === In August 2022, Hart debuted a vegan restaurant, Hart House, to compete with fast-food chains by "offering flavorful plant-based alternatives". The restaurant opened in Los Angeles, California, about a mile from Los Angeles International Airport (LAX), with a simple menu of veggie burgers and Chick'n products. The restaurant's offerings are claimed to be "entirely free of cholesterol, antibiotics, hormones, artificial colors, preservatives, high-fructose corn syrup, or trans fats", and inspired by Hart's own "health nut" lifestyle. Hart opened a second location in Monrovia, California, in November 2022, a third on Sunset Boulevard in Hollywood, California, in May 2023, and a fourth location near the University of Southern California campus in June 2023. All locations closed in September 2024.
However, modern manufactured chalk is mostly gypsum, hydrated calcium sulfate CaSO4·2H2O. Calcium carbonate is a main source for growing biorock. Precipitated calcium carbonate (PCC), pre-dispersed in slurry form, is a common filler material for latex gloves with the aim of achieving maximum saving in material and production costs. Fine ground calcium carbonate (GCC) is an essential ingredient in the microporous film used in diapers and some building films, as the pores are nucleated around the calcium carbonate particles during the manufacture of the film by biaxial stretching. GCC and PCC are used as a filler in paper because they are cheaper than wood fiber. Printing and writing paper can contain 10–20% calcium carbonate. In North America, calcium carbonate has begun to replace kaolin in the production of glossy paper. Europe has been practicing this as alkaline papermaking or acid-free papermaking for some decades. PCC used for paper filling and paper coatings is precipitated and prepared in a variety of shapes and sizes having characteristic narrow particle size distributions and equivalent spherical diameters of 0.4 to 3 micrometers. Calcium carbonate is widely used as an extender in paints, in particular matte emulsion paint where typically 30% by weight of the paint is either chalk or marble. It is also a popular filler in plastics. Some typical examples include around 15–20% loading of chalk in unplasticized polyvinyl chloride (uPVC) drainpipes, 5–15% loading of stearate-coated chalk or marble in uPVC window profile.
The surgeon fabricates a metal foil template derived from the dimensions of the nasal wound. Applying a Doppler ultrasonic scanner, the surgeon identifies the axial pedicle of the tissue-flap (composed of the supraorbital artery and the supratrochlear artery), usually at the base, next to the medial brow; the point usually is between the midline and the supraorbital notch. Tracing the Doppler pulse of the blood flow of the supraorbital artery as far as possible, its delineation is continued as a vertical line, until it intersects with the hairline of the patient. The line extended from the pulse of the blood flow is the central axis of the forehead flap. The length of the flap is determined by placing an un-folded, un-stretched 4 × 4-inch gauze upon the wound, and with it measuring from the pedicle base to the distal (farthest) point of the wound. This measure is the length of the central axis of the skin flap. The template is rotated 180 degrees and placed over the distal (far) portion of the axis of the skin flap; the surgeon outlines it with a surgical marker. The outline markings are continued proximally and parallel to the central axis, maintaining a 2-cm width for the proximal flap. Without applying an injection of anaesthetic epinephrine, the flap is incised (cut), and the distal one-half is elevated between the frontalis muscle and the subcutaneous fat. At approximately the mid-portion of the forehead, the surgeon deepens the plane of the dissection down to the submuscular plane.
== External links == GeneReviews/NCBI/NIH/UW entry on Epimerase Deficiency Galactosemia OMIM entries on Epimerase Deficiency Galactosemia UDPgalactose+4-Epimerase at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.